Blue Owl Capital Holdings’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Blue Owl Capital Holdings’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-515,855	Closed	-$1.11M	–	125
2024 Q3	$1.11M	Buy	515,855 +175,000	+51%	+$629K	0.21%	43
2024 Q2	$1.76M	Hold	340,855	–	–	0.49%	31
2024 Q1	$1.82M	Sell	340,855 -1,152,397	-77%	-$7.97M	0.36%	34
2023 Q4	$8.46M	Buy	+1,493,252	New	+$5.11M	2.02%	13

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Blue Owl Capital Holdings's SYRS Position: Q4 2024 in Review

Blue Owl Capital Holdings sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2024, closing a stake of 515,855 shares — an estimated $1.11M sold.

Blue Owl Capital Holdings first reported a position in SYRS in Q4 2023 and held it in 4 quarters. The position peaked at $8.46M in Q4 2023. 44 funds tracked by Wall St. Rank hold SYRS as of Q4 2024.

Blue Owl Capital Holdings reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Blue Owl Capital Holdings sold 515,855 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $1.11M.
Blue Owl Capital Holdings first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2023 and held it in 4 quarters.
Blue Owl Capital Holdings's Syros Pharmaceuticals, Inc. Common Stock position peaked at $8.46M in Q4 2023.
44 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Blue Owl Capital Holdings's 13F filing for Q4 2024, filed 14 Feb 2025.